Hangzhou-based oncology-focused clinical-stage biotech Bliss Bio has reportedly raised over RMB 100 million (USD 14.7 million) in a Series B+ financing round. The round was led by In Capital, with contributions from Oriental Fortune Capital and Sherpa Healthcare Partners. The proceeds will be used to advance clinical studies for BB-1701, BB-1705, and BB-1709, as well as prepare pre-clinical studies, regulatory filings, and market filings for other pipeline candidates.
Pipeline Development
BB-1709, a potential first-in-class antibody-drug conjugate (ADC) being developed to treat solid tumors, obtained clinical approval in the US last year and has a trial filing under review in China. BB-1701 is an HER2 ADC undergoing a Phase II cohort expansion study. Additionally, BB-1705, another ADC targeting EGFR, is in Phase I study. These programs highlight Bliss Bio’s commitment to advancing innovative oncology therapies.
Future Outlook
With the Series B+ financing, Bliss Bio is poised to accelerate the development of its antibody-drug conjugate pipeline. The funding will support ongoing clinical trials and regulatory submissions, positioning the company to address significant unmet needs in oncology.-Fineline Info & Tech
